Eyepoint Pharmaceuticals (EYPT) Expected to Announce Quarterly Earnings on Thursday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) is projected to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.77) per share and revenue of $3.3290 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:30 AM ET.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.18). The business had revenue of $5.33 million for the quarter, compared to the consensus estimate of $6.82 million. Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. On average, analysts expect Eyepoint Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Eyepoint Pharmaceuticals Trading Down 4.2%

Shares of NASDAQ EYPT opened at $11.73 on Thursday. The firm has a 50 day moving average of $12.80 and a 200 day moving average of $9.99. The firm has a market capitalization of $808.55 million, a price-to-earnings ratio of -4.38 and a beta of 1.95. Eyepoint Pharmaceuticals has a 12-month low of $3.91 and a 12-month high of $14.91.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Eyepoint Pharmaceuticals by 9.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock worth $63,988,000 after buying an additional 600,000 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Eyepoint Pharmaceuticals by 8.5% in the second quarter. Bank of America Corp DE now owns 814,153 shares of the company’s stock worth $7,661,000 after buying an additional 63,941 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Eyepoint Pharmaceuticals by 94.2% in the second quarter. BNP Paribas Financial Markets now owns 172,446 shares of the company’s stock worth $1,623,000 after buying an additional 83,666 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Eyepoint Pharmaceuticals by 199.8% in the second quarter. Invesco Ltd. now owns 128,772 shares of the company’s stock worth $1,212,000 after buying an additional 85,824 shares in the last quarter. Finally, Corient Private Wealth LLC purchased a new position in shares of Eyepoint Pharmaceuticals in the second quarter worth $1,200,000. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on EYPT shares. Chardan Capital restated a “buy” rating and set a $27.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. HC Wainwright upped their price target on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Mizuho set a $28.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Monday, October 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.67.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.